Head and Neck Cancer
Conditions
Keywords
immunotherapy, abemaciclib, pembrolizumab, Cyclin-Dependent Kinase (CDK): CDK4, Cyclin-Dependent Kinase (CDK): CDK6
Brief summary
To assess the objective response rate of tumor lesions to abemaciclib in combination with pembrolizumab in patients with metastatic or recurrent squamous cell carcinoma of head and neck.
Detailed description
Immunotherapy has been recently approved for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. However, only a small percentage of patients experience long-term control, necessitating new therapeutic strategies. Recently, it was shown preclinically and in breast tumors that abemaciclib stimulates production of type III interferons and hence enhances tumor antigen presentation. Abemaciclib also suppressed the proliferation of regulatory T cells. These events promote cytotoxic T-cell-mediated clearance of tumor cells, which is further enhanced by the addition of immune checkpoint blockade. Based on these data, a phase II trial in patients with metastatic or recurrent head and neck cancer who are eligible for immunotherapy is proposed to investigate the combination of abemaciclib with pembrolizumab. Tumor & blood analysis for interferon gamma signature will be explored as possible biomarkers.
Interventions
DRUGCohort 1 Not Previously Treated
Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
DRUGCohort 2 Treated Previously
Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks
Sponsors
University of Alabama at Birmingham
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Histologically confirmed (core biopsy proven) metastatic or recurrent squamous cell carcinoma of head and neck * Adequate pulmonary and cardiac function * Available archived tissue of primary tumor or resected tumor specimen with adequate samples * Prior treatment with immune checkpoint inhibitor is not allowed in cohort 1 patients. Patients in cohort 2 should have failed or progressed on prior immune checkpoint inhibitor * Eastern Cooperative Oncology Group Performance Status(ECOG PS) = 0 or 1 * Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse \[CTCAE\] Grade \<= 1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to randomization. A washout period of at lease 21 days is required between last chemotherapy dose and randomization (provided the patient did not receive radiotherapy) * Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and randomization * The patient is able to swallow oral medications * Adequate hematologic and end-organ function * Absolute Neutrophil Count (ANC) \>= 1500/mm3 * Platelet count ≥ 100,000/mm3 * Hemoglobin (Hb) ≥ 8g/dl (Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion) * Creatinine (Cr) ≤ 1.5 x Upper Limit of Normal (ULN) or Creatinine Clearance (CrCl) ≥ 60 ml/min * Total Bilirubin ≤ 1.5 x ULN (except subjects with Gilbert syndrome, who can have total Bilirubin \< 2.0 x ULN and direct bilirubin within normal limits are permitted.) * Aspartate Aminotransferase (AST) and Alanine aminotransferase (ALT) and alkaline phosphatase ≤ ULN * Agreement to remain abstinent or use appropriate contraception, among women of childbearing potential * Willingness and ability to consent for self to participate in study * Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures
Exclusion criteria
* Autoimmune disease (Note: Vitiligo, type 1 diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement, and conditions not expected to recur in the absence of an external trigger are permitted.) * Condition requiring systemic treatment with either corticosteroids (\>10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days prior to study treatment (Note: Inhaled and topical steroids, and adrenal replacement steroid doses \> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.) * Preexisting medical condition(s) that would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea). * Immunosuppression, of any kind * Prior treatment with Cyclin-Dependent Kinase(CDK) 4/6 Inhibitor * Major surgical procedure or significant traumatic injury within 4 weeks prior to study treatment, and must have fully recovered from any such procedure * Personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest * Angina, myocardial infarction (MI), symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack TIA), arterial embolism, pulmonary embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within 6 months prior to study treatment * Known active viral or non-viral hepatitis or cirrhosis * Any active infection requiring systemic treatment, positive tests for Hepatitis B surface antigen or Hepatitis C ribonucleic acid (RNA). * History of gastrointestinal perforation or fistula in the 6 months prior to study treatment, unless underlying risk has been resolved (e.g., through surgical resection or repair) * Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness * Pregnancy or breastfeeding - Female patients must be surgically sterile (i.e., ≥6 weeks following surgical bilateral oophorectomy with or without hysterectomy or tubal ligation) or be postmenopausal, or must agree to use effective contraception during the study and for 4 months following last dose of treatment. All female patients of reproductive potential must have a negative pregnancy test (serum or urine) within 7 days prior to study treatment. Male patients must be surgically sterile or must agree to use effective contraception during the study and for 4 months following last dose of treatment. * Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or may interfere with the interpretation of study results and, in the judgment of the Investigator, would make the patient inappropriate for this study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| To Assess the Objective Response Rate of Tumor Lesions Using Scans | Baseline | Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants Experiencing Adverse Events Grade 3 or Greater | Baseline to 1 month | Measure adverse events grade 3 or greater to evaluate safety and tolerability |
| To Assess Progression Free Survival (PFS) | baseline to 6 months | Using scan results to assess whether tumor has progressed and the time; |
| To Assess Overall Survival | baseline to 6 months | time that the patient is experiencing survival |
| To Assess the Time to Tumor Response | baseline to 6 months | using scan results to assess the time it takes for the tumor to respond to treatment |
| To Assess the Duration of Response | baseline to 6 months | using scan results to measure the total amount of time that the tumor is responding to treatment |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Cohort 1 Not Previously Treated Patients with metastatic or recurrent head and neck cancer who have not been treated previously with immunotherapy.
Cohort 1 Not Previously Treated: Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks | 1 |
| Cohort 2 Treated Previously Patients with metastatic or recurrent head and neck cancer who have been treated previously with immunotherapy.
Cohort 2 Treated Previously: Abemaciclib 150mg by mouth twice daily Pembrolizumab 200mg IV every 3 weeks | 0 |
| Total | 1 |
Baseline characteristics
| Characteristic | Cohort 1 Not Previously Treated | Cohort 2 Treated Previously | Total |
|---|---|---|---|
| Age, Categorical <=18 years | 0 Participants | 0 Participants | 0 Participants |
| Age, Categorical >=65 years | 1 Participants | 0 Participants | 1 Participants |
| Age, Categorical Between 18 and 65 years | 0 Participants | 0 Participants | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Black or African American | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) More than one race | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants | — | 0 Participants |
| Race (NIH/OMB) White | 1 Participants | — | 1 Participants |
| Region of Enrollment United States | 1 participants | — | 1 participants |
| Sex: Female, Male Female | 0 Participants | — | 0 Participants |
| Sex: Female, Male Male | 1 Participants | — | 1 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | 0 / 1 | 0 / 0 |
| other Total, other adverse events | 1 / 1 | 0 / 0 |
| serious Total, serious adverse events | 0 / 1 | 0 / 0 |
Outcome results
Primary
To Assess the Objective Response Rate of Tumor Lesions Using Scans
Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans
Time frame: Baseline to 8 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Primary
To Assess the Objective Response Rate of Tumor Lesions Using Scans
Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans
Time frame: Baseline to 5 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Primary
To Assess the Objective Response Rate of Tumor Lesions Using Scans
Patients will be evaluated for their tumor response to treatment using RECIST criteria on their scans
Time frame: Baseline
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
Number of Participants Experiencing Adverse Events Grade 3 or Greater
Measure adverse events grade 3 or greater to evaluate safety and tolerability
Time frame: Baseline to 1 month
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
Number of Participants Experiencing Adverse Events Grade 3 or Greater
Measure adverse events grade 3 or greater to evaluate safety and tolerability
Time frame: Baseline to 6 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
Number of Participants Experiencing Adverse Events Grade 3 or Greater
Measure adverse events grade 3 or greater to evaluate safety and tolerability
Time frame: Baseline to 12 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess Overall Survival
time that the patient is experiencing survival
Time frame: baseline to 6 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess Overall Survival
time that the patient is experiencing survival
Time frame: baseline to 12 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess Progression Free Survival (PFS)
Using scan results to assess whether tumor has progressed and the time;
Time frame: baseline to 12 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess Progression Free Survival (PFS)
Using scan results to assess whether tumor has progressed and the time;
Time frame: baseline to 6 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess the Duration of Response
using scan results to measure the total amount of time that the tumor is responding to treatment
Time frame: baseline to 12 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess the Duration of Response
using scan results to measure the total amount of time that the tumor is responding to treatment
Time frame: baseline to 6 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess the Time to Tumor Response
using scan results to assess the time it takes for the tumor to respond to treatment
Time frame: baseline to 6 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination
Secondary
To Assess the Time to Tumor Response
using scan results to assess the time it takes for the tumor to respond to treatment
Time frame: baseline to 12 months
Population: No analysis was performed since study terminated prematurely due to toxicity from other trials with this combination